Lupus Foundation of America Greater Ohio Chapter Logo

Toll Free: 1 (888) NO-LUPUS
Phone: (440) 717-0183

Help Us Solve The Cruel MysteryTM

Donate To The Ohio Chapter

New Biomarker Validated in Lupus Nephritis Research

by | Nov 29, 2022

Inside Lupus Research (ILR): Disease Management News

New research found immunoglobulin-binding protein 1 (IGBP1) to be a valid biomarker for lupus nephritis (LN, lupus-related kidney disease). Researchers investigated IGBP1 because it interacts with another protein that has been associated with increased lupus disease activity.

Ninety-six people were part of the study and divided into three groups: people with lupus and nephritis, people with lupus without nephritis, and people without any history of autoimmune disease (the control group). The study found significant differences between the nephritis and non-nephritis groups regarding disease activity, the main findings include:

  • While both groups (with and without nephritis) had higher IGBP1 levels than the control group, the highest levels were seen in the nephritis group.
  • In the nephritis group, IGBP1 was also associated with proteinuria (high levels of protein in urine which can indicate kidney damage) and renal disease activity.

Lupus is a complex autoimmune disease with LN being a common but serious consequence making biomarker identification and patient monitoring vitally important for detection and treatment. Additional research is needed to gain further insight on IGBP1 and renal activity.

Learn more about lupus and the kidneys.

Read the study

This post was originally published on this site

Skip to content